Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1⁺ Leukemia

详细信息    查看全文

• 作者：Thomas Schmidt¹ ; ² ; ¹⁶ ; ¹⁷ ; Behzad  ; Kharabi Masouleh¹ ; ² ; ¹⁶ ; Sonja Loges¹ ; ² ; ¹⁶ ; ¹⁸ ; Sandra Cauwenberghs¹ ; ² ; Peter Fraisl¹ ; ² ; Christa Maes³ ; Bart Jonckx¹ ; ² ; Kim De  ; Keersmaecker⁴ ; ⁵ ; Maria Kleppe¹ ; ² ; Marc Tjwa¹ ; ² ; Thomas Schenk⁶ ; ⁷ ; Stefan Vinckier¹ ; ² ; Rita Fragoso⁸ ; Maria De  ; Mol¹ ; ² ; Karolien Beel⁵ ; Sé ; rgio Dias⁸ ; Catherine Verfaillie⁹ ; Richard  ; E. Clark¹⁰ ; Tim  ; H. Brc ; mmendorf¹¹ ; ¹² ; Peter Vandenberghe⁵ ; Shahin Rafii¹³ ; Tessa Holyoake¹⁴ ; Andreas Hochhaus⁶ ; ⁷ ; Jan Cools⁴ ; ⁵ ; Michael Karin¹⁵ ; Geert Carmeliet³ ; Mieke Dewerchin¹ ; ² ; Peter Carmeliet¹ ; ² ; ^{peter.carmeliet@vib-kuleuven.be"" rel=""nofollow}
• 刊名：Cancer Cell
• 出版年：2011
• 出版时间：14 June 2011
• 年：2011
• 卷：19
• 期：6
• 页码：740-753
• 全文大小：2125 K

文摘

class=""h3"">Summary

Imatinib has revolutionized the treatment of Bcr-Abl1⁺ chronic myeloid leukemia (CML), but, in most patients, some leukemia cells persist despite continued therapy, while others become resistant. Here, we report that PlGF levels are elevated in CML and that PlGF produced by bone marrow stromal cells (BMSCs) aggravates disease severity. CML cells foster a soil for their own growth by inducing BMSCs to upregulate PlGF, which not only stimulates BM angiogenesis, but also promotes CML proliferation and metabolism, in part independently of Bcr-Abl1 signaling. Anti-PlGF treatment prolongs survival of imatinib-sensitive and -resistant CML mice and adds to the anti-CML activity of imatinib. These results may warrant further investigation of the therapeutic potential of PlGF inhibition for (imatinib-resistant) CML.